Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Gene Editing
6 Articles Available
Can't find what you're looking for? Try our
advanced search
.
CRISPR-Cas9
University of California Granted New CRISPR-Cas9 Patent, Extending its Patent Portfolio for Genome Editing
PR-M03-19-NI-040
Cell and Gene Therapy
Precision BioSciences Aims for Significant Funding Support based on its ARCUS Gene Editing Tech
PAO-M03-19-NI-013
Genome Editing
Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913
PR-M02-19-NI-020
CRISPR
MilliporeSigma Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology
PR-M09-18-NI-046
Gene Editing
Excision BioTherapeutics Licenses UC Berkeley CRISPR Systems
PAO-M11-17-NI-046
Gene Editing
More Gene Editing Technology Being Developed by Novartis
PAO-M11-17-NI-043
